Lexicon Pharmaceuticals, Inc. (LXRX) Investor Relations Documents

Lexicon Pharmaceuticals, Inc. (LXRX) investor relations documents from the company's IR site: 10 presentations, 29 press releases; latest deck 2026-08-06. Read in-app with summaries. First-party data.

Presentation: Lexicon Pharmaceuticals Q2 2026 earnings report highlights the completion of enrollment for the SONATA-HCM Phase 3 trial, with topline data expected in Q1 2027.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-06Press releaseLexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
2026-08-06Earnings deckPresentation
2026-07-30Press releaseLexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-27Press releaseLexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obs
2026-06-03Press releaseLexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
2026-05-28Press releaseLexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-19PresentationPresentation
2026-05-07Press releaseLexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
2026-05-04Press releaseLexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
2026-04-30Press releaseLexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
2026-04-17Press releaseLexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
2026-03-24Press releasePDF Version
2026-03-24Press releaseLexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
2026-03-23Press releasePDF Version
2026-03-23Press releaseLexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
2026-03-16Annual report0001062822-26-000058.pdf
2026-03-11Press releasePDF Version
2026-03-11Press releaseLexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients w
2026-03-05Presentation4th Quarter and Full Year Results 2025 Conference Presentation
2026-03-05Press releaseLexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
2026-03-03Press releasePDF Version
2026-03-03Press releaseLexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
2026-02-26Press releaseLexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
2026-01-21Press releasePDF Version
2026-01-21Press releaseLexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabeti
2026-01-15PresentationJ. P. Morgan 2026 Healthcare Conference
2026-01-12Press releasePDF Version
2026-01-12Press releaseLexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
2026-01-07Press releasePDF Version
2026-01-07Press releaseLexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-11-06Earnings deck3rd Quarter Results 2025 Conference Presentation
Press releasePress Release
2025-10-14PresentationArrowhead Pain Therapeutics Summit Pilavapadin Data
2025-08-06Earnings deck2nd Quarter Results 2025 Conference Presentation
Press releasePress Release
2025-05-13Earnings deck1st Quarter Results 2025 Conference Presentation
Press releasePress Release
2025-04-09Presentation24th Annual Needham VirtualHealthcare Presentation
2025-03-06Presentation4th Quarter and Full Year Results 2024 Conference Presentation
2025-03-06Press releasePress Release

LXRX overview · LXRX earnings · LXRX financials · LXRX KPIs · LXRX documents · LXRX ownership · LXRX peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.